Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Alzheimer's Disease

  Free Subscription


Articles published in JAMA

Retrieve available abstracts of 60 articles:
HTML format



Single Articles


    January 2025
  1. MINTZKER Y
    Blood Biomarkers to Detect Alzheimer Disease.
    JAMA. 2025 Jan 23. doi: 10.1001/jama.2024.25294.
    PubMed    


  2. PALMQVIST S, Hansson O
    Blood Biomarkers to Detect Alzheimer Disease-Reply.
    JAMA. 2025 Jan 23. doi: 10.1001/jama.2024.25297.
    PubMed    


    September 2024
  3. DEVERKA PA, Lin GA, Phillips KA
    Payer Coverage Considerations for Alzheimer Disease Blood-Based Biomarker Tests.
    JAMA. 2024 Sep 30. doi: 10.1001/jama.2024.19084.
    PubMed    


    August 2024
  4. RUBIN R
    A Blood Test for Alzheimer Disease, Repurposing GLP-1s, and Wildfire Smoke-Highlights From the AAIC.
    JAMA. 2024 Aug 16. doi: 10.1001/jama.2024.13816.
    PubMed    


    July 2024
  5. PALMQVIST S, Tideman P, Mattsson-Carlgren N, Schindler SE, et al
    Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care.
    JAMA. 2024 Jul 28:e2413855. doi: 10.1001/jama.2024.13855.
    PubMed     Abstract available


  6. SALLOWAY S, Rowe C, Burns JM
    Are Blood Tests for Alzheimer Disease Ready for Prime Time?
    JAMA. 2024 Jul 28. doi: 10.1001/jama.2024.12814.
    PubMed    


  7. LU Y, Pike JR, Chen J, Walker KA, et al
    Changes in Alzheimer Disease Blood Biomarkers and Associations With Incident All-Cause Dementia.
    JAMA. 2024 Jul 28:e246619. doi: 10.1001/jama.2024.6619.
    PubMed     Abstract available


  8. HARRIS E
    FDA Greenlights Second Alzheimer Drug, Donanemab.
    JAMA. 2024 Jul 26. doi: 10.1001/jama.2024.13386.
    PubMed    


    June 2024
  9. RUBIN R
    A Neurologist Learned He Had Alzheimer Disease 8 Years Ago-Here's What He Wants People to Know.
    JAMA. 2024 Jun 28. doi: 10.1001/jama.2024.10805.
    PubMed    


    May 2024
  10. HARRIS E
    Study: 2 APOE4 Copies May Indicate Genetic Form of Alzheimer Disease.
    JAMA. 2024 May 31. doi: 10.1001/jama.2024.9649.
    PubMed    


  11. THAMBISETTY M, Howard R
    Conveying Risks of Harm in Alzheimer Disease by Amyloid Lowering.
    JAMA. 2024 May 6. doi: 10.1001/jama.2024.7548.
    PubMed    


    April 2024
  12. RUBIN R
    Could GLP-1 Receptor Agonists like Semaglutide Treat Addiction, Alzheimer Disease, and Other Conditions?
    JAMA. 2024 Apr 19. doi: 10.1001/jama.2024.1017.
    PubMed    


    March 2024
  13. KO D, Pascual-Leone A, Shah SJ
    Use of Lecanemab for Patients With Cardiovascular Disease: The Challenge of Uncertainty.
    JAMA. 2024 Mar 15. doi: 10.1001/jama.2024.2991.
    PubMed    


  14. HARRIS E
    Biomarker Changes Can Begin 18 Years Before Alzheimer Disease Diagnosis.
    JAMA. 2024 Mar 6. doi: 10.1001/jama.2024.1568.
    PubMed    


    February 2024
  15. HARRIS E
    Aducanumab Combined With Focused Brain Ultrasound More Effective.
    JAMA. 2024;331:466-467.
    PubMed    


  16. HARRIS E
    Commercial Blood Test May Identify Alzheimer Disease Brain Pathology.
    JAMA. 2024 Feb 7. doi: 10.1001/jama.2024.0175.
    PubMed    


    December 2023
  17. POMARA N, Imbimbo BP
    Use of Donanemab in Early Symptomatic Alzheimer Disease.
    JAMA. 2023;330:2304.
    PubMed    


  18. EVANS CD, Sims JR
    Use of Donanemab in Early Symptomatic Alzheimer Disease-Reply.
    JAMA. 2023;330:2304-2305.
    PubMed    


    November 2023
  19. RAFII MS, Fortea J
    Down Syndrome in a New Era for Alzheimer Disease.
    JAMA. 2023 Nov 22. doi: 10.1001/jama.2023.22924.
    PubMed    


    September 2023
  20. RUBIN R
    Who Should-and Can-Get Lecanemab, the New Alzheimer Disease Drug?
    JAMA. 2023 Sep 27. doi: 10.1001/jama.2023.14443.
    PubMed    


  21. ODOUARD IC, Socal MP, Anderson GF
    Role of Registries in Medicare Coverage of New Alzheimer Disease Drugs.
    JAMA. 2023 Sep 27. doi: 10.1001/jama.2023.17131.
    PubMed    


  22. RUBIN R
    Consumers Can Now Buy a Blood Test to Evaluate Their Alzheimer Disease Risk, but Should They?
    JAMA. 2023 Sep 13. doi: 10.1001/jama.2023.17685.
    PubMed    


    August 2023
  23. HARRIS E
    Study: Identifying Lewy Body Disease Before Symptoms.
    JAMA. 2023;330:686.
    PubMed    


    July 2023
  24. HARRIS E
    MIND Diet No Better Than Control for Adults at Risk of Dementia.
    JAMA. 2023 Jul 26. doi: 10.1001/jama.2023.13134.
    PubMed    


  25. HARRIS E
    Alzheimer Drug Lecanemab Gains Traditional FDA Approval.
    JAMA. 2023 Jul 19. doi: 10.1001/jama.2023.12548.
    PubMed    


  26. SIMS JR, Zimmer JA, Evans CD, Lu M, et al
    Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
    JAMA. 2023 Jul 17:e2313239. doi: 10.1001/jama.2023.13239.
    PubMed     Abstract available


  27. ROSENTHAL MB
    Novel Alzheimer Disease Treatments and Reconsideration of US Pharmaceutical Reimbursement Policy.
    JAMA. 2023 Jul 17. doi: 10.1001/jama.2023.11702.
    PubMed    


  28. MANLY JJ, Deters KD
    Donanemab for Alzheimer Disease-Who Benefits and Who Is Harmed?
    JAMA. 2023 Jul 17. doi: 10.1001/jama.2023.11704.
    PubMed    


  29. RABINOVICI GD, La Joie R
    Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease.
    JAMA. 2023 Jul 17. doi: 10.1001/jama.2023.11703.
    PubMed    


  30. WIDERA EW, Brangman SA, Chin NA
    Ushering in a New Era of Alzheimer Disease Therapy.
    JAMA. 2023 Jul 17. doi: 10.1001/jama.2023.11701.
    PubMed    


  31. HARRIS E
    More Lean Muscle Might Reduce Alzheimer Disease Risk.
    JAMA. 2023 Jul 12. doi: 10.1001/jama.2023.12544.
    PubMed    


    June 2023
  32. HARRIS E
    CMS Will Cover Alzheimer Drugs With Traditional FDA Approval.
    JAMA. 2023 Jun 14. doi: 10.1001/jama.2023.10400.
    PubMed    


  33. HARRIS E
    Brain Cell Biomarker for Preclinical Alzheimer Disease Identified.
    JAMA. 2023 Jun 7. doi: 10.1001/jama.2023.9928.
    PubMed    


    May 2023
  34. HARRIS E
    FDA Greenlights First Drug for Agitation Related to Alzheimer Disease.
    JAMA. 2023 May 24. doi: 10.1001/jama.2023.9153.
    PubMed    


  35. MARCUS R
    New Alzheimer Disease Drugs, Long COVID and the Central Nervous System, and a Nasal Spray for Migraines-Highlights From the 2023 American Academy of Neurology Conference.
    JAMA. 2023 May 10. doi: 10.1001/jama.2023.4389.
    PubMed    


    March 2023
  36. HARRIS E
    Blood Biomarker Helps Distinguish Vascular Dementia.
    JAMA. 2023;329:969.
    PubMed    


    February 2023
  37. HARRIS E
    Healthful Lifestyle May Slow Memory Loss, Even for APOE Gene Carriers.
    JAMA. 2023;329:622.
    PubMed    


  38. LE GUEN Y, Raulin AC, Logue MW, Sherva R, et al
    Association of African Ancestry-Specific APOE Missense Variant R145C With Risk of Alzheimer Disease.
    JAMA. 2023;329:551-560.
    PubMed     Abstract available


    January 2023
  39. LARKIN HD
    Lecanemab Gains FDA Approval for Early Alzheimer Disease.
    JAMA. 2023 Jan 18. doi: 10.1001/jama.2022.24490.
    PubMed    


  40. LARKIN H
    Noninvasive Sensory Stimulation With Light and Sound Tested in Alzheimer Disease.
    JAMA. 2023;329:114.
    PubMed    


    September 2022
  41. HARRIS E
    Large Autopsy Study Estimates Prevalence of "LATE" Neuropathologic Change.
    JAMA. 2022;328:815-816.
    PubMed    


    August 2022
  42. RUBIN R
    Much Anticipated Alzheimer Disease Prevention Trial Finds No Clinical Benefit From Drug Targeting Amyloid; Highlights Need to Consider Other Approaches.
    JAMA. 2022 Aug 17. pii: 2795592. doi: 10.1001/jama.2022.11490.
    PubMed    


  43. DEPEW R
    To My Husband With Alzheimer Disease.
    JAMA. 2022;328:587.
    PubMed    


  44. SLOMSKI A
    Anti-Tau Antibody Semorinemab Fails to Slow Alzheimer Disease.
    JAMA. 2022;328:415.
    PubMed    


    July 2022
  45. SURAN M
    Some Antioxidants May Mitigate the Risk of Dementias.
    JAMA. 2022;328:321.
    PubMed    


    June 2022
  46. RUBIN R
    New Test to Help Diagnose Alzheimer Disease.
    JAMA. 2022;327:2281.
    PubMed    


    May 2022
  47. LARKIN HD
    First Donepezil Transdermal Patch Approved for Alzheimer Disease.
    JAMA. 2022;327:1642.
    PubMed    


    December 2021
  48. SLOMSKI A
    Methylphenidate Treats Apathy in Alzheimer Disease.
    JAMA. 2021;326:2120.
    PubMed    


    October 2021
  49. EMANUEL EJ
    A Middle Ground for Accelerated Drug Approval-Lessons From Aducanumab.
    JAMA. 2021;326:1367-1368.
    PubMed    


    September 2021
  50. ANDERSON TS, Ayanian JZ, Souza J, Landon BE, et al
    Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment.
    JAMA. 2021 Sep 9. pii: 2784225. doi: 10.1001/jama.2021.15286.
    PubMed    


    August 2021
  51. RUBIN R
    CMS Considers Controversial Alzheimer Drug Coverage.
    JAMA. 2021;326:690.
    PubMed    


    July 2021
  52. RUBIN R
    Recently Approved Alzheimer Drug Raises Questions That Might Never Be Answered.
    JAMA. 2021 Jul 21. pii: 2782427. doi: 10.1001/jama.2021.11558.
    PubMed    


  53. SCHULMAN KA, Greicius MD, Richman B
    Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?
    JAMA. 2021 Jul 19. pii: 2782333. doi: 10.1001/jama.2021.11768.
    PubMed    


    June 2021
  54. CHEN MH, Yang FC, Liang CS
    APOE Allele Testing and Alzheimer Disease.
    JAMA. 2021;325:2210-2211.
    PubMed    


  55. CHOUDHURY P, Ramanan VK, Boeve BF
    APOE Allele Testing and Alzheimer Disease-Reply.
    JAMA. 2021;325:2211.
    PubMed    


    April 2021
  56. RUBIN R
    Neurologist Faces His Alzheimer Diagnosis Determined to Lessen Stigma Surrounding the Disease.
    JAMA. 2021 Apr 28. pii: 2779452. doi: 10.1001/jama.2021.5333.
    PubMed    


    March 2021
  57. ALEXANDER GC, Emerson S, Kesselheim AS
    Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility.
    JAMA. 2021 Mar 30. pii: 2778191. doi: 10.1001/jama.2021.3854.
    PubMed    


    January 2021
  58. CHOUDHURY P, Ramanan VK, Boeve BF
    APOE varepsilon4 Allele Testing and Risk of Alzheimer Disease.
    JAMA. 2021 Jan 14. pii: 2775399. doi: 10.1001/jama.2020.15085.
    PubMed    


    November 2020
  59. MADDOX M
    Alzheimer Aubade.
    JAMA. 2020;324:2108.
    PubMed    


    October 2020
  60. TSOU AY, Bulova P, Capone G, Chicoine B, et al
    Medical Care of Adults With Down Syndrome: A Clinical Guideline.
    JAMA. 2020;324:1543-1556.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Alzheimer's Disease is free of charge.